Work

A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.11501

Authors: Mark J. Clemons, Michael Ong, Carol Stober, D. Scott Ernst, Christopher M. Booth, Christina M. Canil, Mihaela Mates, Andrew George Robinson, Phillip S. Blanchette, Anil Abraham Joy, John Frederick Hilton, Olexiy Aseyev, Gregory Russell Pond, Brian Hutton, Ahwon Jeong, Lisa Vandermeer, Dean Fergusson

Institutions: University of Ottawa, Ottawa Hospital, Ottawa Hospital Research Institute, Western University, London Health Sciences Centre, Cancer Care South East, University of Alberta, Cross Cancer Institute, Thunder Bay Regional Health Sciences Centre, NOSM University, McMaster University

Language: English

Topic: Bone health and treatments

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2958818878

Cites:

Cited by: 12

Related to: 10